JP4856294B2 - 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用 - Google Patents

癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用 Download PDF

Info

Publication number
JP4856294B2
JP4856294B2 JP50081799A JP50081799A JP4856294B2 JP 4856294 B2 JP4856294 B2 JP 4856294B2 JP 50081799 A JP50081799 A JP 50081799A JP 50081799 A JP50081799 A JP 50081799A JP 4856294 B2 JP4856294 B2 JP 4856294B2
Authority
JP
Japan
Prior art keywords
group
cancer
nitroxide
prodrug
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50081799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500671A (ja
Inventor
ビー． ミッチェル、ジェイムズ
ラッソウ、アンジェロ
マリー デルーカ、アン
クリシュナ チェルクリ、ミュラリ
Original Assignee
アメリカ合衆国政府
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アメリカ合衆国政府 filed Critical アメリカ合衆国政府
Publication of JP2002500671A publication Critical patent/JP2002500671A/ja
Application granted granted Critical
Publication of JP4856294B2 publication Critical patent/JP4856294B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50081799A 1997-05-27 1998-05-27 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用 Expired - Fee Related JP4856294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4772497P 1997-05-27 1997-05-27
US60/047,724 1997-05-27
PCT/US1998/010685 WO1998053835A1 (en) 1997-05-27 1998-05-27 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009062262A Division JP5270413B2 (ja) 1997-05-27 2009-03-16 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用

Publications (2)

Publication Number Publication Date
JP2002500671A JP2002500671A (ja) 2002-01-08
JP4856294B2 true JP4856294B2 (ja) 2012-01-18

Family

ID=21950574

Family Applications (3)

Application Number Title Priority Date Filing Date
JP50081799A Expired - Fee Related JP4856294B2 (ja) 1997-05-27 1998-05-27 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用
JP2009062262A Expired - Fee Related JP5270413B2 (ja) 1997-05-27 2009-03-16 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用
JP2013003496A Pending JP2013121964A (ja) 1997-05-27 2013-01-11 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009062262A Expired - Fee Related JP5270413B2 (ja) 1997-05-27 2009-03-16 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用
JP2013003496A Pending JP2013121964A (ja) 1997-05-27 2013-01-11 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用

Country Status (10)

Country Link
EP (1) EP0986393B1 (de)
JP (3) JP4856294B2 (de)
AT (1) ATE262330T1 (de)
AU (1) AU746505B2 (de)
CA (1) CA2289017C (de)
DE (1) DE69822626T8 (de)
DK (1) DK0986393T3 (de)
ES (1) ES2216286T3 (de)
PT (1) PT986393E (de)
WO (1) WO1998053835A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
AU765110B2 (en) * 1998-06-26 2003-09-11 Georgetown University Medical Center Compositions and methods for inducing cell death
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
US20070010506A1 (en) * 2003-05-29 2007-01-11 Kenneth Chang Methods of using nitroxides in conjuction with photosensitzers and sonosensitizers
US20120046314A1 (en) * 2005-02-02 2012-02-23 Mitos, Inc. Nitroxides for use in treating or preventing neoplastic disease
EP2139522A2 (de) * 2007-03-06 2010-01-06 Colby Pharmaceutical Company Auf mitochondrien gerichtete kationische antioxidationsverbindungen zur prävention, therapie oder behandlung von hyperproliferativen erkrankungen, neoplasien und karzinomen
US8466130B2 (en) 2009-09-04 2013-06-18 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
US8853277B2 (en) 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
JP2019509352A (ja) * 2016-03-23 2019-04-04 ルイス ハバシュ， ヒトの被験物質をニトロキシドで処理することによってａｐｏｐｔｏｓｉｓ関連遺伝子の発現レベルを増加させる
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758580A (en) * 1985-06-26 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Inhibiting growth of tumors with certain substituted phenoxy dimethyl alkanoic acids, esters or salts
ES2065434T3 (es) * 1990-06-21 1995-02-16 Edith Dr Huland Utilizacion de aerosoles que contienen citocinas y aerosoles que contienen citocinas propiamente dichos.
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
BR9607427A (pt) * 1995-02-16 1998-06-23 Hoffmann La Roche Inibiçao de angiogêne usando interleucina 12

Also Published As

Publication number Publication date
JP2009185034A (ja) 2009-08-20
DE69822626T8 (de) 2005-02-03
PT986393E (pt) 2004-06-30
DE69822626T2 (de) 2004-08-12
DE69822626D1 (de) 2004-04-29
CA2289017C (en) 2008-07-22
EP0986393B1 (de) 2004-03-24
ES2216286T3 (es) 2004-10-16
AU746505B2 (en) 2002-05-02
DK0986393T3 (da) 2004-07-05
JP2002500671A (ja) 2002-01-08
ATE262330T1 (de) 2004-04-15
EP0986393A1 (de) 2000-03-22
JP2013121964A (ja) 2013-06-20
AU7598798A (en) 1998-12-30
CA2289017A1 (en) 1998-12-03
JP5270413B2 (ja) 2013-08-21
WO1998053835A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
JP5270413B2 (ja) 癌の予防および治療処置におけるニトロキシドまたはそのプロドラッグの使用
US9296687B2 (en) Modulators of HSP70/DnaK function and methods of use thereof
JP2888453B2 (ja) ニューモシスティス−カリニ肺炎の治療用または予防用の製薬組成物
US10577315B2 (en) Compositions and methods for treatment of prostate carcinoma
JPH08504211A (ja) 疾患の予防および治療のための酸化防止剤として有用な合成触媒のフリーラジカルスカベンジャー
JP6038933B2 (ja) 粘膜炎の治療および／または予防のためのメラトニンの使用
JP2018048178A (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
EA020526B1 (ru) Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака
Hanson Eicosanoid-induced radioprotection and chemoprotection: laboratory studies and clinical applications
KR20220098144A (ko) 암을 치료하는 데에 사용하기 위한 알파-메틸-dl-티로신의 알킬에스테르
CN105579439A (zh) 辐射减轻性药物制剂
US20070021323A1 (en) Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
KR20170021349A (ko) 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
KR101667362B1 (ko) 방사선 보호용 또는 완화용 약학 조성물
KR20130103650A (ko) (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
JP5138612B2 (ja) メトキシポリエチレングリコールチオエステルキレートおよびその使用
JP6509244B2 (ja) 水晶体硬化抑制剤
JP2000510114A (ja) 抗酸化剤化合物
JP2001509790A (ja) 金属タンパク質分解酵素阻害剤
KR101691536B1 (ko) 신규 fak 저해제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물
US6573296B2 (en) Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity
WO2000010610A2 (en) Drug targeting
Escribano-Lopez et al. Atherosclerosis, Mitochondrial Dysfunction and Oxidative Stress: Mitochondria-Targeted Antioxidants as Potential Therapy. Front
KR20230134092A (ko) 안질환 예방 또는 치료용 약학 조성물
CN117279642A (zh) 用于预防、抑制、治疗或减少动脉瘤的联合疗法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080819

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110824

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111028

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141104

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees